FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
Cleveland Clinic's Eric Boose, M.D., family medicine physician and associate chief medical information officer and Rohit Chandra, executive vice president and…
Headline
The National Institutes of Health April 3 released a study that found an artificial intelligence screening tool was as effective as health care providers in…
Perspective
America’s hospitals and health systems are incubators of innovation, ideas and medical progress as they are constantly striving to improve patient care and…
Headline
A ChatGPT vulnerability identified last year is being used by cyberthreat actors to attack security flaws in artificial intelligence systems, according to a…
Headline
In this conversation, Dave Newman, M.D., vice president and chief medical officer for virtual care at Sanford Health, discusses how innovative virtual care…
Headline
The AHA participated Feb. 18 at ViVE, a health care conference in Nashville focusing on digital health technology. Chris DeRienzo, M.D., AHA senior vice…